Bleomycin is an anticancer drug used against various types of cancers. The aim of this study was to prepare a new PEGylated and non- PEGylated nanoliposomal formulation of bleomycin (PEG- nLip- BLM and nLip- BLM) and evaluate their anticancer activity in different tumor cell lines. The liposomes were prepared by thin- film hydration method, and then, bleomycin (BLM) was loaded to the prepared vesicles. The size, zeta potential, entrapment efficiency, loading rate, release profile, and cytotoxicity of liposomal formulations in TC- 1, LLC1, and HFLF- PI5 cell lines were investigated. Mean particle size and zeta potential of the PEG- nLip- BLM and nLip- BLM were found to be 99.4 ± 4.6 nm and −34.83 ± 4.7 mV; and 112.2 ± 7.2 nm and −27.5 ± 3.2 mV, respectively, which were stable for at least 2 months. Encapsulation and loading efficiency of BLM for PEG- nLip- BLM and nLip- BLM were obtained about 83.1 ± 4.2% and 14.3 ± 2.5%; and 78.3 ± 8.6% and 11.1 ± 3.3%, respectively. Drug release study showed a slow release pattern without considerable burst effect. The liposomal formulations indicated lower toxicity compared to free drug in case of TC- 1 and HFLF- PI5 cells, but their cytotoxicity against LLC1 cells was significantly higher than free drug. The results of this study indicated that PEG- nLip- BLM can be a suitable candidate for drug delivery to solid tumors.
کلید واژگان :bleomycin, cytotoxicity, drug delivery, nanoliposomes
ارزش ریالی : 600000 ریال
با پرداخت الکترونیک